United States Patent 9,814,708: A Detailed Analysis of Scope and Claims
Overview of the Patent
The United States Patent 9,814,708, titled "Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2," is a significant patent in the pharmaceutical sector. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Patent Description
This patent pertains to new pharmaceutical compositions that include deuterated benzoquinoline compounds. These compounds are designed to inhibit the vesicular monoamine transporter 2 (VMAT2), which is crucial in the regulation of neurotransmitter levels in the brain. The patent covers various formulations and methods related to these compounds, including their pharmacokinetics[1][4].
Scope of the Patent
The scope of the patent is broad and encompasses several key areas:
Pharmaceutical Compositions
The patent describes new pharmaceutical compositions that include deuterated benzoquinoline compounds. These compositions can be formulated in various physical forms such as powders, granulates, microbeadlets, microspheres, and pellets. The formulations may involve different excipients and inactive ingredients to enhance stability and bioavailability[1][4].
Methods of Inhibition
The patent details methods for inhibiting VMAT2 using these deuterated compounds. This inhibition is critical for treating conditions related to excessive neurotransmitter release, such as Huntington's disease and other movement disorders[1].
Pharmacokinetics
The pharmacokinetic aspects of the deuterated benzoquinoline compounds are also a key focus. This includes the absorption, distribution, metabolism, and excretion (ADME) profiles of these compounds, which are essential for understanding their efficacy and safety in clinical settings[1].
Claims of the Patent
The claims of the patent are the most critical part, as they define the legal boundaries of the invention.
Independent Claims
The patent includes several independent claims that cover the pharmaceutical compositions, methods of preparation, and methods of use. For example, Claim 1 might describe a pharmaceutical composition comprising a deuterated benzoquinoline compound and a pharmaceutically acceptable excipient[1].
Dependent Claims
Dependent claims further specify the independent claims by adding additional limitations. These could include specific formulations, dosages, or methods of administration. For instance, a dependent claim might specify a particular ratio of the active compound to the excipient or a specific method of preparing the formulation[1].
Patent Landscape
Understanding the patent landscape is crucial for assessing the competitive environment and potential legal challenges.
Related Patents
Other patents related to benzoquinoline compounds and VMAT2 inhibitors are part of the broader patent landscape. These include patents on similar formulations, methods of inhibition, and pharmacokinetic studies. For example, US Patent Application 20210244723A1 also deals with deuterated benzoquinoline compounds and their use in inhibiting VMAT2[4].
Patent Analytics
Patent analytics tools can help in mapping the patent landscape by categorizing patents by claims and scope concepts. This can reveal gaps or opportunities in the intellectual property portfolio and help in strategic decision-making. Tools like ClaimScape® software can generate interactive claim charts to review patent coverage and identify areas for future development[3].
Legal and Administrative Challenges
The patent landscape is also influenced by legal and administrative challenges.
Inter Partes Review (IPR)
The Patent Trial and Appeal Board (PTAB) can be a significant factor in the patent landscape. IPR and post-grant review (PGR) procedures allow for administrative challenges to the validity of patents. This can impact the enforceability of the patent and the overall intellectual property strategy of the patent holder[5].
Controversies and Criticisms
PTAB procedures have been controversial, with critics arguing that they are biased against patent holders and create uncertainty in patent rights. This can affect the investment in innovation and the overall value of the patent portfolio[5].
Strategic Implications
For companies holding or interested in this patent, several strategic implications arise:
Claim Coverage Matrix
Using a Claim Coverage Matrix can help in understanding which patents and claims are actively protecting the intellectual property and where gaps or opportunities exist. This tool is essential for managing a large portfolio of patents and claims[3].
Future Design Opportunities
The interactive claim charts generated by tools like ClaimScape® can help engineers, scientists, and management in identifying new design options and future directions. This is particularly useful in a rapidly evolving field like pharmaceuticals[3].
Key Takeaways
- Pharmaceutical Compositions: The patent covers new pharmaceutical compositions including deuterated benzoquinoline compounds.
- Methods of Inhibition: The patent details methods for inhibiting VMAT2, crucial for treating certain neurological conditions.
- Pharmacokinetics: The patent includes detailed pharmacokinetic studies of the deuterated compounds.
- Claims: The patent includes independent and dependent claims that define the scope of the invention.
- Patent Landscape: The patent is part of a broader landscape that includes related patents and potential legal challenges.
- Legal and Administrative Challenges: PTAB procedures like IPR can impact the enforceability of the patent.
FAQs
What is the main focus of United States Patent 9,814,708?
The main focus of this patent is on new pharmaceutical compositions comprising deuterated benzoquinoline compounds and their methods to inhibit vesicular monoamine transporter 2 (VMAT2).
What are the key components of the pharmaceutical compositions described in the patent?
The compositions include deuterated benzoquinoline compounds and various excipients and inactive ingredients to enhance stability and bioavailability.
How does the patent impact the treatment of neurological conditions?
The patent's focus on inhibiting VMAT2 is crucial for treating conditions such as Huntington's disease and other movement disorders by regulating neurotransmitter levels.
What role does PTAB play in the patent landscape?
PTAB, through procedures like IPR and PGR, allows for administrative challenges to the validity of patents, which can impact the enforceability and value of the patent.
How can patent analytics tools help in managing the patent portfolio?
Patent analytics tools like ClaimScape® help in categorizing patents by claims and scope concepts, identifying gaps or opportunities, and generating interactive claim charts to review patent coverage.
Sources
- US9814708B2 - Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 - Google Patents
- Patent Claims Research Dataset - USPTO
- Patent Analytics - Intellectual Property Law
- US20210244723A1 - Google Patents
- The Patent Trial and Appeal Board and Inter Partes Review - Congressional Research Service
